Stephen L. Brown

This study examines how genomic background and developmental state affect signaling pathways and therapy response in GBM patient-derived cells, finding that differentiation increases TMZ resistance and activates DNA-damage interferon responses.

This study shows BUB1 inhibition enhances the effectiveness of radiotherapy and chemoradiation in lung cancer cell lines.

This study identifies BUB1 as a regulator of non-homologous end joining (NHEJ) in triple-negative breast cancer (TNBC), showing that its inhibition sensitizes TNBC cells to radiotherapy.